TY - JOUR
T1 - Cost-Utility of Routine Testing in Chronic Urticaria/Angioedema
T2 - A Cohort Study
AU - Carrillo-Martin, Ismael
AU - Dudgeon, Matthew G.
AU - Chamorro-Pareja, Natalia
AU - Haehn, Daniela A.
AU - Rivera-Valenzuela, Maritza G.
AU - Spaulding, Aaron C.
AU - Heckman, Michael G.
AU - Diehl, Nancy N.
AU - Irizarry-Alvarado, Joan M.
AU - Helmi, Haytham
AU - Gonzalez-Estrada, Alexei
N1 - Funding Information:
Funding was provided by the Mayo Clinic Florida Focused Research Team Program. The funds were destined to cover for statisticians' hours and reports. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Publisher Copyright:
© 2019 American Academy of Allergy, Asthma & Immunology
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Background: Chronic urticaria/angioedema (CUA) guidelines recommend limiting tests to diagnose and assess prognosis, activity, and severity. Routine testing in CUA might substantially increase cost of disease without benefiting outcome. Objective: To evaluate the utility of tests in CUA and how they influence the cost of disease. Methods: We reviewed 725 electronic medical records of patients who were evaluated for CUA between 2010 and 2018 at a tertiary care center. The sample was gathered through the search of International Classification of Diseases Ninth and Tenth Revision codes pertaining to CUA. Analyses were made to evaluate changes in outcome for patients on whom at least 1 test was performed to evaluate CUA, the costs generated by these tests, and the tendencies to order specific tests from 2010 through 2018. Results: Of 725 patients (age median, 47 years; women, 73.1%), 543 (74.8%) had at least 1 test performed. Tests had an elevated percentage of normal results (>90%). Five patients (0.9%) had a change in outcome and 8 patients were given a different diagnosis (0.1% each). Evaluation, management, and tests accounted for most of the costs. Costs remain similar between 2010-2014 (mean, $569) and 2015-2018 (mean, $569). Conclusions: In CUA, tests rarely uncover underlying conditions or lead to changes in management and outcome, but they substantially increase the costs generated by the disease. Adherence to current recommendations to limit testing might help in reducing the financial burden of CUA and improve delivery of care.
AB - Background: Chronic urticaria/angioedema (CUA) guidelines recommend limiting tests to diagnose and assess prognosis, activity, and severity. Routine testing in CUA might substantially increase cost of disease without benefiting outcome. Objective: To evaluate the utility of tests in CUA and how they influence the cost of disease. Methods: We reviewed 725 electronic medical records of patients who were evaluated for CUA between 2010 and 2018 at a tertiary care center. The sample was gathered through the search of International Classification of Diseases Ninth and Tenth Revision codes pertaining to CUA. Analyses were made to evaluate changes in outcome for patients on whom at least 1 test was performed to evaluate CUA, the costs generated by these tests, and the tendencies to order specific tests from 2010 through 2018. Results: Of 725 patients (age median, 47 years; women, 73.1%), 543 (74.8%) had at least 1 test performed. Tests had an elevated percentage of normal results (>90%). Five patients (0.9%) had a change in outcome and 8 patients were given a different diagnosis (0.1% each). Evaluation, management, and tests accounted for most of the costs. Costs remain similar between 2010-2014 (mean, $569) and 2015-2018 (mean, $569). Conclusions: In CUA, tests rarely uncover underlying conditions or lead to changes in management and outcome, but they substantially increase the costs generated by the disease. Adherence to current recommendations to limit testing might help in reducing the financial burden of CUA and improve delivery of care.
KW - Changes in outcome
KW - Chronic urticaria
KW - Costs
KW - Tests
KW - Utility
UR - http://www.scopus.com/inward/record.url?scp=85065907207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065907207&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2019.04.031
DO - 10.1016/j.jaip.2019.04.031
M3 - Article
C2 - 31054327
AN - SCOPUS:85065907207
SN - 2213-2198
VL - 7
SP - 2823
EP - 2832
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -